Reported 9 months ago
Taiwanese precision healthcare leader Precious Life (4117) held a shareholders' meeting announcing its 2023 financial results, showing a revenue of NT$265 million and a net loss of NT$200 million. Despite challenges from the global pandemic reducing demand for COVID-19 testing products, the company continues to expand globally and develop new technologies, focusing on personalized diagnostics and precision medicine. Precious Life has received recognition for its cancer molecular diagnostics product and is collaborating with partners to develop a chemical luminescence immunoassay platform. The company is also preparing to launch a new AI campus building at the Zhupei AI Smart Park, aiming to enhance the biomedical industry using big data and AI technology while strengthening its presence in the major health field.
Source: YAHOO